Stacking Up SUPN Against Its Peers – Is It Still a Buy?
Here is how Supernus Pharmaceuticals (SUPN) stacks up against its peers in size, valuation, growth and margin.
- SUPN’s operating margin of 10.7% is strong, but lowest among peers; LLY has 43.0%.
- SUPN’s revenue growth of 5.5% in the last 12 months is moderate, outpacing JNJ, JAZZ but lagging LLY, ZTS, NVS.
- SUPN gained 26.8% in the past year and trades at a PE of 37.0, outperforming its peers.
As a quick background, Supernus Pharmaceuticals provides development and commercialization of CNS disease treatments, including extended-release epilepsy and migraine medication, marketed through wholesalers, specialty pharmacies, and distributors in the U.S.
| SUPN | LLY | JNJ | ZTS | JAZZ | NVS | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.4 | 593.1 | 419.9 | 68.2 | 6.8 | 223.4 |
| Revenue ($ Bil) | 0.7 | 53.3 | 89.3 | 9.3 | 4.1 | 53.2 |
| PE Ratio | 37.0 | 43.0 | 19.3 | 27.1 | -16.8 | 17.4 |
| LTM Revenue Growth | 5.5% | 36.8% | 4.3% | 6.3% | 4.5% | 11.5% |
| LTM Operating Margin | 10.7% | 43.0% | 24.7% | 37.0% | 15.0% | 29.8% |
| LTM FCF Margin | 27.9% | -0.1% | 20.8% | 24.6% | 30.3% | 27.9% |
| 12M Market Return | 26.8% | -26.2% | 13.8% | -15.5% | 6.8% | 11.4% |
Why does this matter? SUPN just went up 25.8% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell SUPN Stock to see if Supernus Pharmaceuticals holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through SUPN Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| SUPN | 5.5% | 8.9% | -8.9% | 15.1% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| JNJ | 4.3% | 4.3% | 6.5% | 1.6% |
| ZTS | 6.3% | 8.3% | 5.7% | 3.9% |
| JAZZ | 4.5% | 6.1% | 4.8% | 18.3% |
| NVS | 11.5% | 10.8% | 7.4% | -1.2% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| SUPN | 10.7% | 11.4% | 2.2% | 6.8% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| JNJ | 24.7% | 24.9% | 27.5% | 26.3% |
| ZTS | 37.0% | 36.6% | 35.9% | 36.2% |
| JAZZ | 15.0% | 17.9% | 15.6% | 14.0% |
| NVS | 29.8% | 28.1% | 20.9% | 18.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| SUPN | 27.4 | 27.0 | 1199.3 | 31.5 |
| LLY | 50.7 | 65.7 | 100.1 | 52.8 |
| JNJ | 16.9 | 24.8 | 11.3 | 25.8 |
| ZTS | 27.7 | 29.8 | 38.8 | 32.5 |
| JAZZ | -16.0 | 13.6 | 18.8 | -44.5 |
| NVS | 18.5 | 16.4 | 14.1 | 28.4 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.